𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞: 𝐔𝐧𝐥𝐨𝐜𝐤𝐢𝐧𝐠 𝐜𝐚𝐩𝐢𝐭𝐚𝐥 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐧𝐞𝐱𝐭 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐛𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐬 Last Thursday, our partner Olivier Litzka joined a great panel at the IZBrunch event at the Innovation and Startup Center for Biotechnology (IZB) in Munich, organized together with Bio-M. 💬 The discussion brought together biotech bankers, investors and entrepreneurs to explore the funding landscape for life science companies — from early-stage to IPOs and beyond — and to address the challenges of today’s market environment. Olivier emphasized the strengths of the German biotech ecosystem – its underlying cutting-edge innovation, its resulting product, and its motivated people. He stressed the need for full focus and concentration on product development was needed in the face of the current headwinds, but also reminded the audience that the industry is here to stay and grow, no matter what, as the need for truly new medicines remains independent of market cycles. 👏 Many thanks to IZB and Bio-M for hosting such a timely event!
💲Funding the Future: Unlocking Capital for the Next Biotech Breakthroughs💲 Following the success of the first IZBrunch Investment Special, co-hosted by BioM Biotech Cluster Development GmbH, we kicked off round two today at the IZB - Innovation and Start-up Center Biotechnology—this time focusing on funding models beyond state support. From venture capital and strategic partnerships to crowdfunding, we explored innovative ways to fuel the next wave of biotech advancements. Given the recent developments in the USA, the topic of financing was more important than ever, and there was a high demand for discussion within the biotech community. The panel, hosted by Managing Director of BioM Ralf Huss, featured the following speakers: 🎤 Thomas Klein – Founder & CEO at PIRCHE, leading innovation in digital diagnostics for transplant matching. 🎤 Olivier Litzka - Partner at Andera Partners, driving biotech and medtech investments across Europe. 🎤 Uli Kinzel - Partner & Head of Healthcare Europe at Bryan, Garnier & Co., leading M&A and investment banking in the pharma and healthcare sector. 🎤 Elena Lovo, PhD - Head of Life Sciences EMEA at J.P. Morgan, supporting biotech, medtech, and health tech innovation. Key Takeaways: 💡 Uncertainty is the new normal – but we’ve faced it before, and we’ll get through it again. The key? Community, resilience, and a focus on the fundamentals. 💡 M&A remains constant, but the types of companies being acquired are shifting. Big players look for proven innovation, while smaller, trendy ideas compete in a crowded market. 💡 IPO markets remain challenging, but selective IPOs are still successful, especially when driven by strong pipelines and innovative therapies. The rebound of biotech IPOs is expected as the market stabilizes and investors regain confidence. 💡 Internationalisation is key – global expertise can boost credibility and open new funding doors. 💡 Crowdfunding is an emerging option, with new EU regulations opening doors for biotech fundraising. Despite the challenges in fundraising and market uncertainty, one thing remains clear: the biotech ecosystem has been through difficult times before, and it will again—but perseverance, innovation, and strong networks will always push us forward.🚀 Thank you to our speakers, host and the lively audience for your valuable contributions. We look forward to more engaging discussions in our future events! #IZB #venturecapital #biotechinvestment #crowdfunding